Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more
Recce Pharmaceuticals Ltd (RECEF) - Total Liabilities
Latest total liabilities as of June 2025: $15.47 Million USD
Based on the latest financial reports, Recce Pharmaceuticals Ltd (RECEF) has total liabilities worth $15.47 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Recce Pharmaceuticals Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Recce Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Recce Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
USA | $16.50 Million |
|
GOLFZON Co. Ltd
KQ:215000
|
Korea | ₩176.43 Billion |
|
Journey Medical Corp
NASDAQ:DERM
|
USA | $59.29 Million |
|
Kuang Hong Arts Management
TWO:6596
|
Taiwan | NT$969.97 Million |
|
Pennar Industries Limited
NSE:PENIND
|
India | ₹22.62 Billion |
|
Foraco International SA
PINK:FRACF
|
USA | $154.69 Million |
|
Daol Investment & Securities
KO:030210
|
Korea | ₩10.21 Trillion |
|
Tetamat Gida Yatirimlari AS
IS:TETMT
|
Turkey | TL215.09 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Recce Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Recce Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Recce Pharmaceuticals Ltd (2013–2025)
The table below shows the annual total liabilities of Recce Pharmaceuticals Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $15.47 Million | -2.69% |
| 2024-06-30 | $15.89 Million | +208.93% |
| 2023-06-30 | $5.14 Million | +100.79% |
| 2022-06-30 | $2.56 Million | +117.54% |
| 2021-06-30 | $1.18 Million | +26.44% |
| 2020-06-30 | $931.53K | -29.84% |
| 2019-06-30 | $1.33 Million | +195.84% |
| 2018-06-30 | $448.82K | -48.67% |
| 2017-06-30 | $874.44K | +322.85% |
| 2016-06-30 | $206.80K | -24.10% |
| 2015-06-30 | $272.47K | +33.69% |
| 2014-06-30 | $203.81K | +31.86% |
| 2013-06-30 | $154.57K | -- |